REGISTERED NUMBER:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Statements for the Year Ended 31 December 2020 |
|
for |
|
IBA Molecular UK Limited |
REGISTERED NUMBER:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Statements for the Year Ended 31 December 2020 |
|
for |
|
IBA Molecular UK Limited |
IBA Molecular UK Limited (Registered number: 04794962) |
|
|
|
|
|
|
Contents of the Financial Statements |
for the Year Ended 31 December 2020 |
|
|
|
|
Page |
|
Company Information | 1 |
|
Balance Sheet | 2 |
|
Notes to the Financial Statements | 3 |
|
IBA Molecular UK Limited |
|
Company Information |
for the Year Ended 31 December 2020 |
|
|
|
|
|
|
|
DIRECTOR: |
|
|
|
|
|
|
SECRETARY: |
|
|
|
|
|
|
REGISTERED OFFICE: |
|
|
|
|
|
|
|
|
|
|
REGISTERED NUMBER: |
|
|
|
|
|
|
AUDITORS: |
|
and Chartered Accountants |
Elm House, Tanshire Park |
Shackleford Road, Elstead |
Godalming |
Surrey |
GU8 6LB |
IBA Molecular UK Limited (Registered number: 04794962) |
|
Balance Sheet |
31 December 2020 |
|
31.12.20 | 31.12.19 |
Notes | £ | £ |
CURRENT ASSETS |
Debtors: amounts falling due within one year | 4 |
|
|
Debtors: amounts falling due after more than
one year |
4 |
|
|
Cash in hand |
|
|
|
|
CREDITORS |
Amounts falling due within one year | 5 |
|
|
NET CURRENT ASSETS |
|
|
TOTAL ASSETS LESS CURRENT
LIABILITIES |
|
|
|
PROVISIONS FOR LIABILITIES | 6 |
|
|
NET ASSETS |
|
|
|
CAPITAL AND RESERVES |
Called up share capital |
|
|
Retained earnings |
( |
) |
( |
) |
|
|
|
|
|
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
|
The financial statements were approved by the director and authorised for issue on
|
|
|
|
|
|
|
|
IBA Molecular UK Limited (Registered number: 04794962) |
|
Notes to the Financial Statements |
for the Year Ended 31 December 2020 |
|
1. | STATUTORY INFORMATION |
|
IBA Molecular UK Limited is a
|
|
2. | ACCOUNTING POLICIES |
|
Basis of preparing the financial statements |
|
|
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
|
Current or deferred taxation assets and liabilities are not discounted. |
|
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
|
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
|
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
|
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
|
Foreign currencies |
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
|
Decommissioning provision |
A decommissioning provision is recognised when a site is constructed to provide for the expected costs payable to decommission it in accordance with the lease agreements and local regulatory requirements. |
|
The provisions are calculated by management with reference to the work of external experts in the field and are discounted to reflect the time value of money where this is material. |
|
Going concern |
At the balance sheet date the company's current liabilities exceeded its assets due within one year. However, the Directors are confident of the continued support of the holding company and consequently the accounts have been prepared on a going concern basis. |
|
3. | EMPLOYEES AND DIRECTORS |
|
The average number of employees during the year was NIL (2019 - NIL). |
IBA Molecular UK Limited (Registered number: 04794962) |
|
Notes to the Financial Statements - continued |
for the Year Ended 31 December 2020 |
|
4. | DEBTORS |
31.12.20 | 31.12.19 |
£ | £ |
Amounts falling due within one year: |
Trade debtors |
|
|
Other debtors |
|
|
|
|
|
Amounts falling due after more than one year: |
Other debtors |
|
|
|
Aggregate amounts |
|
|
|
5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.12.20 | 31.12.19 |
£ | £ |
Trade creditors |
|
|
Taxation and social security |
|
|
Other creditors |
|
|
|
|
|
6. | PROVISIONS FOR LIABILITIES |
|
The provision relates to estimated decommissioning costs for equipment. As this equipment is no longer owned by IBA Molecular UK Limited and agreements are in place such that these costs will be borne by the current owners of the equipment, an equal debit balance is included in debtors falling due in more than one year. |
|
7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006 |
|
The Report of the Auditors was unqualified. |
|
|
for and on behalf of
|
|
8. | RELATED PARTY DISCLOSURES |
|
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |
|
9. | ULTIMATE CONTROLLING PARTY |
|
The company is a wholly owned subsidiary of Curium International SA, a company incorporated in Belgium. The ultimate holding company is GLO New TopCo SCA, a company incorporated in Luxembourg. |
|
The smallest group for which consolidated accounts are prepared is Curium MidCo S.à r.l., a company registered in Luxembourg, with registered office at 13, rue Aldringen, L-1118 Luxembourg, Grand Duchy of Luxembourg. |